Transition Therapeutics Stock Price, News & Analysis (NASDAQ:TTHI)

$1.52 0.00 (0.00 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$1.52
Today's Range$1.52 - $1.57
52-Week Range$0.66 - $2.75
Volume12,400 shs
Average Volume70,238 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Transition Therapeutics (NASDAQ:TTHI)

Transition Therapeutics logoTransition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.

Receive TTHI News and Ratings via Email

Sign-up to receive the latest news and ratings for TTHI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:TTHI
CUSIPN/A
Phone+1-416-2607770

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($1.07)
Net IncomeN/A
Net MarginsN/A
Return on Equity-58.00%
Return on Assets-47.29%

Miscellaneous

EmployeesN/A
Outstanding Shares38,880,000

Transition Therapeutics (NASDAQ:TTHI) Frequently Asked Questions

What is Transition Therapeutics' stock symbol?

Transition Therapeutics trades on the NASDAQ under the ticker symbol "TTHI."

How were Transition Therapeutics' earnings last quarter?

Transition Therapeutics Inc (NASDAQ:TTHI) issued its quarterly earnings data on Tuesday, September, 15th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.39) by $0.08. View Transition Therapeutics' Earnings History.

Who are some of Transition Therapeutics' key competitors?

How do I buy Transition Therapeutics stock?

Shares of Transition Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Transition Therapeutics' stock price today?

One share of Transition Therapeutics stock can currently be purchased for approximately $1.52.

How can I contact Transition Therapeutics?

Transition Therapeutics' mailing address is 101 College St Suite 220, TORONTO, ON M5G 1L7, Canada. The biopharmaceutical company can be reached via phone at +1-416-2607770.


MarketBeat Community Rating for Transition Therapeutics (TTHI)

Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  160
MarketBeat's community ratings are surveys of what our community members think about Transition Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Transition Therapeutics (NASDAQ:TTHI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AHoldHold
Consensus Rating Score: N/AN/A2.002.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$1.50
Price Target Upside: N/AN/AN/A100.00% upside

Transition Therapeutics (NASDAQ:TTHI) Consensus Price Target History

Price Target History for Transition Therapeutics (NASDAQ:TTHI)

Transition Therapeutics (NASDAQ:TTHI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2016CowenReiterated RatingHoldN/AView Rating Details
4/19/2016Canaccord GenuityReiterated RatingHoldN/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Transition Therapeutics (NASDAQ:TTHI) Earnings History and Estimates Chart

Earnings by Quarter for Transition Therapeutics (NASDAQ:TTHI)

Transition Therapeutics (NASDAQ TTHI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/15/2015Q415($0.39)($0.31)ViewN/AView Earnings Details
5/12/2015Q315($0.20)($0.11)ViewN/AView Earnings Details
2/10/2015($0.24)($0.38)ViewN/AView Earnings Details
11/12/2014Q312($0.18)($0.45)ViewN/AView Earnings Details
9/26/2014($0.28)($0.39)ViewN/AView Earnings Details
5/14/2014($0.07)($0.16)ViewN/AView Earnings Details
11/12/2013($0.11)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Transition Therapeutics (NASDAQ:TTHI) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Transition Therapeutics (NASDAQ:TTHI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Transition Therapeutics (NASDAQ TTHI)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Transition Therapeutics (NASDAQ TTHI) News Headlines

Source:
DateHeadline
Transition Therapeutics (TTHI) versus KalVista Pharmaceuticals (KALV) Head to Head ReviewTransition Therapeutics (TTHI) versus KalVista Pharmaceuticals (KALV) Head to Head Review
www.americanbankingnews.com - November 24 at 11:40 AM
Contrasting Sonoma Pharmaceuticals (SNOA) & Transition Therapeutics (TTHI)Contrasting Sonoma Pharmaceuticals (SNOA) & Transition Therapeutics (TTHI)
www.americanbankingnews.com - November 4 at 9:28 PM
Head to Head Analysis: Transition Therapeutics (TTHI) and MediWound (MDWD)Head to Head Analysis: Transition Therapeutics (TTHI) and MediWound (MDWD)
www.americanbankingnews.com - October 26 at 5:34 AM
Roger Crystal Went to Business School to Learn How to Treat AddictionRoger Crystal Went to Business School to Learn How to Treat Addiction
www.bloomberg.com - October 25 at 1:40 AM
Analyzing Transition Therapeutics (TTHI) & Its RivalsAnalyzing Transition Therapeutics (TTHI) & Its Rivals
www.americanbankingnews.com - October 16 at 12:08 AM
Analyzing Transition Therapeutics (TTHI) and Kamada (KMDA)Analyzing Transition Therapeutics (TTHI) and Kamada (KMDA)
www.americanbankingnews.com - September 23 at 12:26 AM
Critical Contrast: Transition Therapeutics (TTHI) and Its RivalsCritical Contrast: Transition Therapeutics (TTHI) and Its Rivals
www.americanbankingnews.com - September 19 at 4:26 PM
Financial Survey: Catalyst Biosciences (CBIO) vs. Transition Therapeutics (TTHI)Financial Survey: Catalyst Biosciences (CBIO) vs. Transition Therapeutics (TTHI)
www.americanbankingnews.com - August 25 at 4:30 PM
Transition Therapeutics (NASDAQ:TTHI) and Peregrine Pharmaceuticals (PPHM) Head to Head SurveyTransition Therapeutics (NASDAQ:TTHI) and Peregrine Pharmaceuticals (PPHM) Head to Head Survey
www.americanbankingnews.com - August 12 at 2:04 PM
Head-To-Head Survey: Transition Therapeutics (TTHI) vs. Onconova Therapeutics (ONTX)Head-To-Head Survey: Transition Therapeutics (TTHI) vs. Onconova Therapeutics (ONTX)
www.americanbankingnews.com - August 12 at 12:30 AM
OPKO Health (OPK) Announces Transition Therapeutics (TTHI) Shareholder Approval of Proposed AcquisitionOPKO Health (OPK) Announces Transition Therapeutics (TTHI) Shareholder Approval of Proposed Acquisition
www.streetinsider.com - August 26 at 10:49 AM
Transition Therapeutics (TTHI) Commences Dosing in TT701 Phase 2 in Androgen Deficiency - StreetInsider.comTransition Therapeutics (TTHI) Commences Dosing in TT701 Phase 2 in Androgen Deficiency - StreetInsider.com
www.streetinsider.com - April 26 at 9:48 AM
Transition: Lilly Not To Advance Diabetes Drug Candidate TT401 To Phase 3Transition: Lilly Not To Advance Diabetes Drug Candidate TT401 To Phase 3
www.nasdaq.com - April 18 at 9:57 AM
Transition Therapeutics (TTHI) Says Lilly (LLY) Wont Advance TT401 into Phase 3Transition Therapeutics (TTHI) Says Lilly (LLY) Won't Advance TT401 into Phase 3
www.streetinsider.com - April 18 at 9:57 AM
Transition Therapeutics Provides Update On Type 2 Diabetes Drug Candidate TT401Transition Therapeutics Provides Update On Type 2 Diabetes Drug Candidate TT401
www.thestreet.com - April 18 at 6:34 AM

SEC Filings

Transition Therapeutics (NASDAQ:TTHI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Transition Therapeutics (NASDAQ:TTHI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Transition Therapeutics (NASDAQ TTHI) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.